AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26046622 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait-retraining intervention
Number of subjects: 23
Study 23811974 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MS
Number of subjects: 48
Study 23811974 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients with MS
Number of subjects: 48
Study 23811974 — intervention group
Group type: COMPARATOR
Intervention: Male control subjects
Number of subjects: 48
Study 23811974 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients with MS
Number of subjects: 48
Study 21466679 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 180
Study 21466679 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 180
Study 21466679 — intervention group
Group type: EXPERIMENTAL
Intervention: PV
Number of subjects: 180
Study 19793962 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation to second-order faces with happy and sad expressions using local directions of moving random dots on a static-dot background.
Number of subjects: 0
Study 19793962 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding static random dots to first-order faces to match the background of adapting motion faces.
Number of subjects: 0
Study 19793962 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-face adaptation with added noise that matched correlation statistics of real faces or natural images.
Number of subjects: 0
Study 16931609 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (0.3 g/kg/d)
Number of subjects: 102
Study 16931609 — intervention group
Group type: COMPARATOR
Intervention: Control group (isonitrogenous placebo supplementation - alanine)
Number of subjects: 102
Study 15451912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin levels, BMI, waist-to-hip ratio
Number of subjects: 559
Study 15451912 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic and diastolic blood pressures
Number of subjects: 559
Study 15451912 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hour postload plasma glucose (2-h PG), serum insulin, fasting plasma glucose
Number of subjects: 559
Study 15451912 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total cholesterol and triglycerides
Number of subjects: 559
Study 15451912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of systolic and diastolic blood pressure
Number of subjects: 559
Study 15451912 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary albumin excretion rate
Number of subjects: 559
Study 11163499 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation alone (Arm A)
Number of subjects: 231
Study 11163499 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation with DFMO (Arm B)
Number of subjects: 231
Study 11163499 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionated irradiation (Arm C)
Number of subjects: 231
Study 11163499 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionated irradiation with DFMO (Arm D)
Number of subjects: 231
Study 9255764 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC) administered at 0, 1, and 2 months
Number of subjects: 0
Study 9255764 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC)
Number of subjects: 0
Study 9255764 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC
Number of subjects: 0
Study 9255764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7685425 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg, four doses orally starting the night before ESWL)
Number of subjects: 24
Study 7685425 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 24
Study 7685425 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 24
Study 7685425 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 31647902 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Electrical Stimulation (GES) ON (14 Hz, 5 mA, pulses of 330 μs)
Number of subjects: 172
Study 31647902 — intervention group
Group type: COMPARATOR
Intervention: Control (GES OFF)
Number of subjects: 172
Study 31647902 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Electrical Stimulation (GES) ON
Number of subjects: 172
Study 29196161 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping over upper trapezius (UT)
Number of subjects: 54
Study 29196161 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping over middle trapezius (MT)
Number of subjects: 54
Study 29196161 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping over lower trapezius (LT)
Number of subjects: 54
Study 28370401 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2) plus G-CSF and pre-emptive/rescue plerixafor
Number of subjects: 30
Study 28370401 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2) plus G-CSF
Number of subjects: 30
Study 28370401 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2)
Number of subjects: 30
Study 26510013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education plus supervised physical activity 3 days/week
Number of subjects: 42
Study 26510013 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education only
Number of subjects: 42
Study 24103532 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 66
Study 21716073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 2 mg
Number of subjects: 35
Study 21716073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 10 mg
Number of subjects: 35
Study 21716073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Number of subjects: 35
Study 21716073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19194375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cholinergic receptor blockade (scopolamine 4 microg/kg bodyweight intravenously and mecamylamine 5 mg orally)
Number of subjects: 0
Study 19194375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19194375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cholinergic receptor blockade
Number of subjects: 0
Study 16704676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of splinting, tendon‐ and nerve‐gliding exercises
Number of subjects: 28
Study 16704676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment in combination with splinting
Number of subjects: 28
Study 16704676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ultrasound, splinting, tendon‐ and nerve‐gliding exercises
Number of subjects: 28
Study 16704676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of splinting, exercise and ultrasound therapy
Number of subjects: 28
Study 15679252 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with surgery
Number of subjects: 0
Study 15679252 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation without surgery
Number of subjects: 0
Study 15679252 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 11316542 — intervention group
Group type: EXPERIMENTAL
Intervention: Hfx RT with daily carboplatin/etoposide (50 mg each)
Number of subjects: 195
Study 11316542 — intervention group
Group type: COMPARATOR
Intervention: Hfx RT with daily carboplatin/etoposide (30 mg each) and weekend carboplatin/etoposide (100 mg each)
Number of subjects: 195
Study 9027276 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (20 mg/kg/day, three 100-mg tablets four times daily for 28 days)
Number of subjects: 187
Study 9027276 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three placebo tablets four times daily for 28 days)
Number of subjects: 187
Study 9027276 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucantime (20 mg of intramuscular antimony/kg per day for 20 days)
Number of subjects: 187
Study 8276046 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of SDZ MKS 492 (40 mg)
Number of subjects: 0
Study 8276046 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled SDZ MKS 492 (12 mg)
Number of subjects: 0
Study 8276046 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled SDZ MKS 492 (10 mg and 20 mg)
Number of subjects: 0
Study 8276046 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled SDZ MKS 492
Number of subjects: 0
Study 3561330 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin and cefamandole (TC)
Number of subjects: 100
Study 3561330 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin and cefamandole with tobramycin (TCT)
Number of subjects: 100
Study 29716471 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Security (COS) group intervention
Number of subjects: 52
Study 29716471 — intervention group
Group type: COMPARATOR
Intervention: Standard-mother-infant treatment (TAU)
Number of subjects: 52
Study 26935334 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin inhalation solution (LIS) 240mg twice daily for 28 days
Number of subjects: 88
Study 26935334 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin inhalation solution (LIS)
Number of subjects: 88
Study 24694461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding after PCI
Number of subjects: 4329
Study 24694461 — intervention group
Group type: COMPARATOR
Intervention: No bleeding
Number of subjects: 4329
Study 24694461 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-access-site bleeding
Number of subjects: 4329
Study 24694461 — intervention group
Group type: EXPERIMENTAL
Intervention: Access-site bleeding
Number of subjects: 4329
Study 22830446 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 2314
Study 22830446 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2314
Study 20378601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan (100 mg·day(‐1) for 7 days)
Number of subjects: 35
Study 20378601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 18803046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 22
Study 16533589 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored genetic counseling (CTGC)
Number of subjects: 54
Study 16533589 — intervention group
Group type: COMPARATOR
Intervention: Standard genetic counseling (SGC)
Number of subjects: 54
Study 14640991 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.88+/‐0.13 mg)
Number of subjects: 10
Study 14640991 — intervention group
Group type: EXPERIMENTAL
Intervention: GH+acipimox 250 mg b.i.d.
Number of subjects: 10
Study 14640991 — intervention group
Group type: COMPARATOR
Intervention: Acipimox b.i.d. (no GH)
Number of subjects: 10
Study 10985874 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable automatic lancing devices with trigger‐linked lancet movement
Number of subjects: 50
Study 10985874 — intervention group
Group type: EXPERIMENTAL
Intervention: Devices with a blade
Number of subjects: 50
Study 10985874 — intervention group
Group type: EXPERIMENTAL
Intervention: Devices producing blood volumes > 50 microl
Number of subjects: 50
Study 10985874 — intervention group
Group type: EXPERIMENTAL
Intervention: Two of the devices
Number of subjects: 50
Study 10985874 — intervention group
Group type: EXPERIMENTAL
Intervention: All disposable automatic lancing devices
Number of subjects: 50
Study 8853083 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 to 7% sevoflurane in 66% nitrous oxide/28% oxygen by face mask until tracheal intubation (treatment 1)
Number of subjects: 20
Study 8853083 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 to 7% sevoflurane without nitrous oxide to tracheal intubation (treatment 2)
Number of subjects: 20
Study 8853083 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 to 7% sevoflurane in 66% nitrous oxide/28% oxygen by face mask until laryngeal mask airway insertion (treatment 3)
Number of subjects: 20
Study 1535877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ionic contrast medium (diatrizoate sodium)
Number of subjects: 150
Study 1535877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nonionic contrast medium (iohexol)
Number of subjects: 150
Study 1535877 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nonionic contrast medium (iohexol)
Number of subjects: 150
Study 6526201 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate Ointment (ISDN-O): 300 mg daily
Number of subjects: 20
Study 6526201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30878411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nebulized epinephrine (0.1 mg/kg; maximum 1 mg)
Number of subjects: 84
Study 30878411 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose nebulized epinephrine (0.5 mg/kg; maximum 5 mg)
Number of subjects: 84
Study 29205440 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reflection procedure
Number of subjects: 42
Study 29205440 — intervention group
Group type: COMPARATOR
Intervention: Alternative diagnoses (control group)
Number of subjects: 42
Study 26957110 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9857 (100 mg once daily for 3 days)
Number of subjects: 0
Study 26957110 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9857 (50-300 mg once daily for 3 days)
Number of subjects: 0
Study 26957110 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9857
Number of subjects: 0
Study 26957110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25202935 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral lumbar fusion (PLF)
Number of subjects: 81
Study 25202935 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 81
Study 23111749 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring of intraocular pressure and blood pressure measurements
Number of subjects: 70
Study 20398447 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 20398447 — intervention group
Group type: COMPARATOR
Intervention: Collagen injection
Number of subjects: 0
Study 18059586 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (400 IU vitamin E + 1 g vitamin C)
Number of subjects: 48
Study 18059586 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable powder (FV)
Number of subjects: 48
Study 18059586 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 48
Study 18059586 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (A)
Number of subjects: 48
Study 18059586 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (A) and FV
Number of subjects: 48
Study 16918747 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition-specific computerized templates for urinary incontinence (UI)
Number of subjects: 0
Study 16918747 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition-specific computerized templates for falls
Number of subjects: 0
Study 12794024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifyllin (PTX) 30 mg/kg/day
Number of subjects: 31
Study 12794024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PTX)
Number of subjects: 31
Study 10695096 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine GITS 20 mg once daily
Number of subjects: 49
Study 10695096 — intervention group
Group type: COMPARATOR
Intervention: nifedipine retard 10 mg twice daily
Number of subjects: 49
Study 8934359 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 14
Study 8934359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg)
Number of subjects: 14
Study 8934359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1913770 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrose (S) and sucrose-Duraphat (SD)
Number of subjects: 187
Study 1913770 — intervention group
Group type: EXPERIMENTAL
Intervention: invert sugar (I) and invert sugar-Duraphat (ID)
Number of subjects: 187
Study 1913770 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat (D)
Number of subjects: 187
Study 1913770 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 187
Study 6347085 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU + adriamycin + levamisole (LMS)
Number of subjects: 167
Study 6347085 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU + adriamycin (control group)
Number of subjects: 167
Study 31835039 — intervention group
Group type: EXPERIMENTAL
Intervention: ALCAM measured at admission
Number of subjects: 5165
Study 29550150 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU vitamin D3 supplementation
Number of subjects: 179
Study 29550150 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3 supplementation
Number of subjects: 179
Study 29550150 — intervention group
Group type: COMPARATOR
Intervention: Control group (400 IU)
Number of subjects: 179
Study 28415973 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARE intervention
Number of subjects: 5091
Study 28415973 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5091
Study 25662474 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 46
Study 25662474 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment (2-day admission)
Number of subjects: 46
Study 25662474 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 46
Study 24615574 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Computer-Assisted Self-Interviewing (ACASI)
Number of subjects: 0
Study 24615574 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face Interviewing (FTFI)
Number of subjects: 0
Study 24615574 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Personal Interviewing (CAPI)
Number of subjects: 0
Study 22703383 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related desynchronization (ERD) during hand motor imagery in ALS patients
Number of subjects: 19
Study 22703383 — intervention group
Group type: COMPARATOR
Intervention: Event-related desynchronization (ERD) during hand motor imagery in healthy control subjects
Number of subjects: 19
Study 22703383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulbar function in ALS patients
Number of subjects: 19
Study 22703383 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor function of the upper extremities in ALS patients
Number of subjects: 19
Study 19799783 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill with manual assistance (TM)
Number of subjects: 51
Study 19799783 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill with electrical stimulation (TS)
Number of subjects: 51
Study 19799783 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground with electrical stimulation (OG)
Number of subjects: 51
Study 19799783 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill with locomotor robot (LR)
Number of subjects: 51
Study 19799783 — intervention group
Group type: COMPARATOR
Intervention: Non-disabled (ND) individuals walking at preferred speed
Number of subjects: 51
Study 19799783 — intervention group
Group type: COMPARATOR
Intervention: Non-disabled (ND) individuals walking at slower speed and using a walker
Number of subjects: 51
Study 17577468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous/oral linezolid
Number of subjects: 163
Study 17577468 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vancomycin
Number of subjects: 163
Study 15101639 — intervention group
Group type: EXPERIMENTAL
Intervention: Maglev train sounds (Transrapid 08)
Number of subjects: 0
Study 11570615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 110
Study 11570615 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 110
Study 11570615 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 110
Study 11570615 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 110
Study 9458998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid balance monitoring for two weeks (Group A)
Number of subjects: 12
Study 9458998 — intervention group
Group type: COMPARATOR
Intervention: No fluid balance monitoring (Group B)
Number of subjects: 12
Study 7698835 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% prednicarbate cream used twice daily over 5 days
Number of subjects: 143
Study 7698835 — intervention group
Group type: COMPARATOR
Intervention: 0.25% prednicarbate cream with didecyldimethylammoniumchloride
Number of subjects: 143
Study 2937812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Number of subjects: 10
Study 2937812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg
Number of subjects: 10
Study 2937812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1,000 mg
Number of subjects: 10
Study 2937812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (all doses)
Number of subjects: 10
Study 31232530 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (epoetin β)
Number of subjects: 48
Study 31232530 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP
Number of subjects: 48
Study 31232530 — intervention group
Group type: COMPARATOR
Intervention: Urine assays
Number of subjects: 48
Study 29338124 — intervention group
Group type: EXPERIMENTAL
Intervention: HC (Hot Compresses)
Number of subjects: 149
Study 29338124 — intervention group
Group type: EXPERIMENTAL
Intervention: HC plus tobramycin
Number of subjects: 149
Study 29338124 — intervention group
Group type: EXPERIMENTAL
Intervention: HC plus tobramycin/dexamethasone
Number of subjects: 149
Study 29338124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions that completely resolved
Number of subjects: 149
Study 27814869 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic treatment (four sessions over two weeks comprising passive lumbar foramen opening and neurodynamic sliders plus home exercises)
Number of subjects: 60